Valeo Pharma Inc. · OTC:VPHIF
Valeo Pharma — Investor Presentation (November 2022)
28 slides from Valeo Pharma's investor presentation, November 2022
Slide 1: Corporate Presentation November 2022
Valeo Stands for Innovation, Innovation Sparks Life Corporate Presentation November 2022 (TSX: VPH) (OTCQB: VPHIF)
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Forward-Looking Statements: This presentation, including the documents incorporated by reference herein, contains “forward-looking information” as defined under Canadian securities laws (collectively, “forward-looking statements”). All statements other than statements of h
Slide 3: Who We Are
WHO WE ARE Overview - Founded in 2003 - Fully integrated pharmaceutical company - Dedicated to commercialization of prescription products in Canada - Licenses / acquires Canadian rights to commercial stage drugs - Pure commercial play, No R&D or manufacturing - Industry leading growth rate PAGE 3 -
Slide 4: Business Units
3 Business Units Ophthalmology BUSINESS UNITS Respiratory / Allergy Respiratory Allergy XIIDRA® SIMBRINZA® ENERZAIR® ALLERJECT® PAGE 4 ATECTURA® Specialty Products 8 Spec. Products Neurology Oncology REDESCA® ONSTRYV® YONDELIS® TSX:VPH M-ESLON® SABIZABULIN
Slide 5: Transformative Launches
2021-2022 Transformative Product Additions TRANSFORMATIVE LAUNCHES Revenues 160 Q4-21 Launch: ENERZAIR® Q4-22 Launch: XIIDRA® 140 ATECTURA® SIMBRINZA® 120 ALLERJECT® Q3-21 Launch: REDESCA® 100 Millions 80 PAGE 5 60 40 20 0 FY-20 A FY-21 A FY-22 E FY-23 F FY-24 F FY-25 F Ophthalmology Respiratory / A
Slide 6: Product Portfolio
PRODUCT PORTFOLIO FAST Growing Commercial Products Portfolio Launched Est. Peak Sales Est. 2022 Est. 2023 RESPIRATORY / ALLERGY /Acquired ($M) Revenues Revenues ENERZAIR® Asthma 2021 $90 + ATECTURA® Asthma 2021 $30 + $5M $16M ALLERJECT® Allergy 2022 $25 + Total $145 OPHTHALMOLOGY PAGE 6 XIIDRA® Dry
Slide 7: Respiratory / Allergy Business Unit
Respiratory / Allergy Business Unit Launched Est. Peak Sales Est. 2022 Est. 2023 RESPIRATORY / ALLERGY /Acquired ($M) Revenues Revenues ENERZAIR® Asthma 2021 $90 + ATECTURA® Asthma 2021 $30 + $5M $16M ALLERJECT® Allergy 2022 $25 + Total $145
Slide 8: Asthma: Canadian Dynamics
ASTHMA: CANADIAN DYNAMICS Asthma: Canadian Market Dynamics ➢ Canadian asthma sufferers: 3.8 M ➢ Targeted Patient Population: 1.0 M ➢ % of asthma sufferers with uncontrolled symptoms: 50% + ➢ Canadians under chronic treatment: 1.4 M Triple Therapy : Fastest growing ➢ E.R. Visits (2015) from severe as
Slide 9: Enerzair & Atectura Breezhaler
ENERZAIR / ATECTURA ENERZAIR & ATECTURA BREEZHALER Enerzair Atectura Launched Q4-21, Q4-21, First in Class Best in Class Target Market 350k Patients 615K Patients Triple Agent Therapy Peak Sales $90M $30M PAGE 9 % of Patients @ Peak 43% 14 % Share of New 69% 7% Prescriptions Partner Novartis Canada
Slide 10: Clinical Results
CLINICAL RESULTS ENERZAIR ® / ATECTURA® Clinical Results First in class Best in class triple combination Dual combination ICS/LABA/LAMA LABA/ICS ENERZAIR ENERZAIR ATECTURA vs Vs vs ADVAIR LOOSE TRIPLE Rate ratio (95% Cl) ADVAIR Rate ratio (95% Cl) 1.0 - 0.78 (0.66, 0.93) 0.74 (0.61, 0.91) 0.9 - +96m
Slide 11: Prescription Trends
PRESCRIPTION TRENDS Prescription Trends TRX # of Prescribers TRX 1,100 22,000 GPFM SPEC 1,004 ATECTURA AT TRX ENERZAIR EN TRX 20,201 1,000 20,000 883 900 18,000 16,875 779 800 16,000 683 13,669 700 14,000 PAGE 11 600 558 12,000 10,865 500 447 10,000 8,102 400 353 8,000 5,966 300 265 6,000 198 4,195
Slide 12: NBRx vs Comps
NBRx trend among the competition Rolling Quarter Data NBRx – Sept. 22 NBRX vs COMPS. 24,984 25,000 20,000 PAGE 12 15,000 9,472 10,000 5,000 4,019 3,440 2,697 1,382 1,315 773 0 Symbicort Advair + Gx Breo Ellipta Zenhale AT + EN Enerzair Atectura Trelegy Ellipta $275M + $160M + $114M + $52M + TSX:VPH
Slide 13: Allerject
ALLERJECT® ALLERJECT Licensed: Q3-2022 Partner Kaléo, Inc. (US) Target market: 1M units / YR Market Size: $80M + / CAGR 5-8% PAGE 13 Peak Sales: $25M / 30% market share Calendar 2021 sales: $4M / ~5% market share IMPORTANT : Allerject at 36% market share before re-engineering Product re-launched in
Slide 14: Allerject Advantages
ALLERJECT ADVANTAGES Competitive Advantages vs Market Leader Features Epipen Allerject (Market leader) Annual Revenues $75-80M $4-5M Pricing $95-105 Same Reimbursement 75% coverage Same Voice activated No Yes FDA Guidance for Device Reliability N.A. First to meet 99.999% PAGE 14 User Friendly Averag
Slide 15: Ophthalmology Business Unit
Ophthalmology Business Unit Launched Est. Peak Sales Est. 2022 Est. 2023 OPHTHALMOLOGY /Acquired ($M) Revenues Revenues XIIDRA® Dry eye disease 2022 $30M + $5M $25M SIMBRINZA® Glaucoma 2022 $15M + Total $45M
Slide 16: Xiidra: Dry Eye Disease
XIIDRA XIIDRA®: Dry Eye Disease Licensed : Q3-2022 Partner: Novartis Target Market: 8M people, 2% treated with RX PAGE 16 Current Market Share: 31% 2021 Sales: $15M Peak Sales: $30M + Market CAGR: 5-6% TSX:VPH
Slide 17: Simbrinza: Glaucoma
SIMBRINZA®: Glaucoma SIMBRINZA Licensed: Q3-2022 Partner: Novartis Target Market: 400,000 Canadians 2021 Sales: $8M PAGE 17 Current Market Share: 18% Peak Sales: $15M + Market CAGR: 4-5% TSX:VPH
Slide 18: Xiidra & Simbrinza Revenues
XIIDRA & SIMBRINZA REVENUES Xiidra – Simbrinza Gross Revenues Valeo acquires PEAK SALES 50,000,000 commercial rights >$40m (July 22) 40,000,000 XIIDRA Net TO SIMBRINZA Net TO 30,000,000 PAGE 18 20,000,000 10,000,000 0 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Xiidra: “Unpromoted” since
Slide 19: Specialty Products Business Unit
Specialty Products Business Unit SPECIALTY PRODUCTS Launch Est. Peak Sales Est. 2022 Est. 2023 / Acquired (M) Revenues Revenues REDESCA® Blood Thinner 2021 $25 + M-ESLON® Pain (Tablet) 2016 $10 $17M $22M SABIZABULIN Covid-19 (ARDS) 2022 TBD Others Parkinson/Oncology 2020 $5 + Total $40
Slide 20: Redesca (Biosimilar)
Redesca® (Biosimilar) REDESCA Launch: Q2-2021 Target market: $180M Peak sales: $25M Partner: Shenzhen Techdow Pharmaceuticals, PAGE 20 (World largest Heparin manufacturer) Phase 1 Phase 2 Phase 3 2021-22 2022-23 2022-26 Primary Market – Rest of Canada Secondary Early Adopter (Ont, Maritimes, Market
Slide 21: Biosimilar Market
BIOSIMILAR MARKET LMWH Biosimilar Market insight CDH Sept.-22 Monthly - IQVIA Enoxaparin MS - Un Biosimilar MS 100% 100% 90% 90% 80% 80% 45% 70% 70% 60% PAGE 21 60% 50% 50% 40% 30% 40% 20% 30% 10% 20% 0% 10% Apr- May- Jun- Jul- Aug- Sep- Oct- Nov- Dec- Jan- Feb- Mar- Apr- May- Jun- Jul- Aug- Sep- 0%
Slide 22: Financials and Summary
Financials and Summary
Slide 23: Sequential P&L Improvement – Q4-22 Jump
Sequential P&L Improvement – Q4-22 JUMP! P&L IMPROVEMENTS • Q3-22 Record Revenues – up 27% over Q2-22 Quarterly Revenues and Margins • Q3-22 Record Margins – up 34% over Q2-22 $12,000 Xiidra • YTD Q3-22 Record Revenues – up 48% $10,000 Simbrinza Allerject • YTD Q3-22 Record YTD Margins – up 63% Q4-2
Slide 24: Years of Growth
YEARS OF GROWTH Q3-22 Transactions to fuel growth for many years Revenues (millions $) ▪ 6 major brands to drive 160 top line and margin expansion for 5+ years 140 Xiidra Simbrinza ▪ New products to help 120 Allerject DOUBLE Valeo’s revenues 100 Q4-22 PAGE 24 ▪ Peaks Sales now Exceeds 80 Redesca lau
Slide 25: Leadership Team
LEADERSHIP TEAM Leadership MANAGEMENT BOARD Steve Saviuk Richard J. MacKay Maureen C. Brennan Founder, CEO Chairman Board Member Founder and CEO Since 2003 Former Vice-Chairman 40+ years in private and of Stiefel Laboratories public health sector Former Director General Frederic Fasano Steve Saviuk
Slide 26: Capital Structure
Capital Structure, as at Nov. 7, 22 CAPITAL STRUCTURE CAPITALIZATION MILLIONS Shares Outstanding (Share Price - $0.66) 81.6 Options/RSUs (avg. price, $0.87) 6.9 Warrants (avg. strike price $1.02) 14.1 Convertible debentures ($25.7M) 23.6 Management & Insiders PAGE 26 aligned with Fully-Diluted Share
Slide 27: Investment Thesis
INVESTMENT THESIS Investment Thesis - Industry leading topline growth 2022+++ - Pure commercial play, NO R&D / manufacturing - 6 growth assets launched/acquired last 2 yrs. - Significant growth of peak sales potential(≥ $230M) PAGE 27 - Significant operating leveraging - More products to come / be a
Slide 28: Contact Us
Contact Us PHONE 514-694-0150 EMAIL [email protected] WEB www.valeopharma.com